136 related articles for article (PubMed ID: 12817992)
1. Conditional mouse models demonstrate oncogene-dependent differences in tumor maintenance and recurrence.
Tilli MT; Furth PA
Breast Cancer Res; 2003; 5(4):202-5. PubMed ID: 12817992
[TBL] [Abstract][Full Text] [Related]
2. Impact of p53 loss on reversal and recurrence of conditional Wnt-induced tumorigenesis.
Gunther EJ; Moody SE; Belka GK; Hahn KT; Innocent N; Dugan KD; Cardiff RD; Chodosh LA
Genes Dev; 2003 Feb; 17(4):488-501. PubMed ID: 12600942
[TBL] [Abstract][Full Text] [Related]
3. Wnt-1 and int-2 mammary oncogene effects on the beta-catenin pathway in immortalized mouse mammary epithelial cells are not sufficient for tumorigenesis.
Hollmann CA; Kittrell FS; Medina D; Butel JS
Oncogene; 2001 Nov; 20(52):7645-57. PubMed ID: 11753642
[TBL] [Abstract][Full Text] [Related]
4. Signal transduction pathways activated and required for mammary carcinogenesis in response to specific oncogenes.
Amundadottir LT; Leder P
Oncogene; 1998 Feb; 16(6):737-46. PubMed ID: 9488037
[TBL] [Abstract][Full Text] [Related]
5. Preferential activation of Fgf8 by proviral insertion in mammary tumors of Wnt1 transgenic mice.
Kapoun AM; Shackleford GM
Oncogene; 1997 Jun; 14(24):2985-9. PubMed ID: 9205106
[TBL] [Abstract][Full Text] [Related]
6. Isoform-specific ras activation and oncogene dependence during MYC- and Wnt-induced mammary tumorigenesis.
Jang JW; Boxer RB; Chodosh LA
Mol Cell Biol; 2006 Nov; 26(21):8109-21. PubMed ID: 16908535
[TBL] [Abstract][Full Text] [Related]
7. Differential gene expression in mouse mammary adenocarcinomas in the presence and absence of wild type p53.
Cui XS; Donehower LA
Oncogene; 2000 Dec; 19(52):5988-96. PubMed ID: 11146550
[TBL] [Abstract][Full Text] [Related]
8. c-MYC induces mammary tumorigenesis by means of a preferred pathway involving spontaneous Kras2 mutations.
D'Cruz CM; Gunther EJ; Boxer RB; Hartman JL; Sintasath L; Moody SE; Cox JD; Ha SI; Belka GK; Golant A; Cardiff RD; Chodosh LA
Nat Med; 2001 Feb; 7(2):235-9. PubMed ID: 11175856
[TBL] [Abstract][Full Text] [Related]
9. Evidence that transgenes encoding components of the Wnt signaling pathway preferentially induce mammary cancers from progenitor cells.
Li Y; Welm B; Podsypanina K; Huang S; Chamorro M; Zhang X; Rowlands T; Egeblad M; Cowin P; Werb Z; Tan LK; Rosen JM; Varmus HE
Proc Natl Acad Sci U S A; 2003 Dec; 100(26):15853-8. PubMed ID: 14668450
[TBL] [Abstract][Full Text] [Related]
10. In vitro and in vivo antisense-mediated growth inhibition of a mammary adenocarcinoma from MMTV-neu transgenic mice.
Sacco MG; Barbieri O; Piccini D; Noviello E; Zoppé M; Zucchi I; Frattini A; Villa A; Vezzoni P
Gene Ther; 1998 Mar; 5(3):388-93. PubMed ID: 9614559
[TBL] [Abstract][Full Text] [Related]
11. In vivo evidence supporting a metastasis suppressor role for Stard13 (Dlc2) in ErbB2 (Neu) oncogene induced mouse mammary tumors.
Basak P; Leslie H; Dillon RL; Muller WJ; Raouf A; Mowat MRA
Genes Chromosomes Cancer; 2018 Apr; 57(4):182-191. PubMed ID: 29218825
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of potential oncogene alterations in the ENU1564 rat mammary tumor model.
Hal DG; Stoica G
Anticancer Res; 1994; 14(2A):481-7. PubMed ID: 7912494
[TBL] [Abstract][Full Text] [Related]
13. Absence of p53 in a mouse mammary tumor model promotes tumor cell proliferation without affecting apoptosis.
Jones JM; Attardi L; Godley LA; Laucirica R; Medina D; Jacks T; Varmus HE; Donehower LA
Cell Growth Differ; 1997 Aug; 8(8):829-38. PubMed ID: 9269892
[TBL] [Abstract][Full Text] [Related]
14. Pathway pathology: histological differences between ErbB/Ras and Wnt pathway transgenic mammary tumors.
Rosner A; Miyoshi K; Landesman-Bollag E; Xu X; Seldin DC; Moser AR; MacLeod CL; Shyamala G; Gillgrass AE; Cardiff RD
Am J Pathol; 2002 Sep; 161(3):1087-97. PubMed ID: 12213737
[TBL] [Abstract][Full Text] [Related]
15. Cellular dormancy in minimal residual disease following targeted therapy.
Ruth JR; Pant DK; Pan TC; Seidel HE; Baksh SC; Keister BA; Singh R; Sterner CJ; Bakewell SJ; Moody SE; Belka GK; Chodosh LA
Breast Cancer Res; 2021 Jun; 23(1):63. PubMed ID: 34088357
[TBL] [Abstract][Full Text] [Related]
16. Control of the three-dimensional growth pattern of mammary epithelium: role of genes of the Wnt and erbB families studied using reconstituted epithelium.
Edwards PA
Biochem Soc Symp; 1998; 63():21-34. PubMed ID: 9513708
[TBL] [Abstract][Full Text] [Related]
17. Specific protection against breast cancers by cyclin D1 ablation.
Yu Q; Geng Y; Sicinski P
Nature; 2001 Jun; 411(6841):1017-21. PubMed ID: 11429595
[TBL] [Abstract][Full Text] [Related]
18. The role of p53 loss in genomic instability and tumor progression in a murine mammary cancer model.
Donehower LA; Godley LA; Aldaz CM; Pyle R; Shi YP; Pinkel D; Gray J; Bradley A; Medina D; Varmus HE
Prog Clin Biol Res; 1996; 395():1-11. PubMed ID: 8895979
[No Abstract] [Full Text] [Related]
19. WAP-TAg transgenic mice and the study of dysregulated cell survival, proliferation, and mutation during breast carcinogenesis.
Li M; Lewis B; Capuco AV; Laucirica R; Furth PA
Oncogene; 2000 Feb; 19(8):1010-9. PubMed ID: 10713684
[TBL] [Abstract][Full Text] [Related]
20. Lack of sustained regression of c-MYC-induced mammary adenocarcinomas following brief or prolonged MYC inactivation.
Boxer RB; Jang JW; Sintasath L; Chodosh LA
Cancer Cell; 2004 Dec; 6(6):577-86. PubMed ID: 15607962
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
